Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of COVID-19 patients.
The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.
Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.
VIDEO: Messi Mania Hits Kolkata! Fans Throng Airport, Streets Crowded As Fans Set Off Fireworks To Welcome Argentina Legend
Mumbai News: BMC Puts Prime 23,822 Sq m Lower Parel Land Parcel On Lease After Supreme Court Win; Expects ₹1,348 Crore Revenue
Bombay HC Grants Bail To Alleged LeT Operative Accused Of 2010 Nashik Reconnaissance Case; Cites Over 10 Years In Jail And Trial Delays
Bombay HC: Magistrate Cannot Order Blocking Of Online Content Under IT Act; Upholds Stay On Contempt Plea Against Google
